BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1298 related articles for article (PubMed ID: 33770348)

  • 21. Evolution of SARS-CoV-2: A prediction on the lineages and vaccine effectiveness.
    Priyanka ; Choudhary OP; Singh I
    Travel Med Infect Dis; 2021; 40():101983. PubMed ID: 33548551
    [No Abstract]   [Full Text] [Related]  

  • 22. SARS-CoV-2 mRNA Vaccines Elicit Different Responses in Immunologically Naïve and Pre-Immune Humans.
    Forgacs D; Jang H; Abreu RB; Hanley HB; Gattiker JL; Jefferson AM; Ross TM
    Front Immunol; 2021; 12():728021. PubMed ID: 34646267
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rapid and Quantitative Detection of Human Antibodies against the 2019 Novel Coronavirus SARS CoV2 and Its Variants as a Result of Vaccination and Infection.
    Taubner B; Peredo-Wende R; Ramani A; Singh G; Strle K; Cady NC
    Microbiol Spectr; 2021 Oct; 9(2):e0089021. PubMed ID: 34585942
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mucosal IgA response elicited by intranasal immunization of Lactobacillus plantarum expressing surface-displayed RBD protein of SARS-CoV-2.
    Li L; Wang M; Hao J; Han J; Fu T; Bai J; Tian M; Jin N; Zhu G; Li C
    Int J Biol Macromol; 2021 Nov; 190():409-416. PubMed ID: 34499954
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The conundrum of current anti-SARS-CoV-2 vaccines.
    Federico M
    Cytokine Growth Factor Rev; 2021 Aug; 60():46-51. PubMed ID: 33714693
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of Pfizer/BioNTech and Oxford/AstraZeneca vaccines against COVID-19 morbidity and mortality in real-world settings at countrywide vaccination campaign in Saudi Arabia.
    Meo SA; Fahad Al-Jassir F; Al-Qahtani S; Albarrak R; Usmani AM; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Nov; 25(22):7185-7191. PubMed ID: 34859883
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antibody and T cell immune responses following mRNA COVID-19 vaccination in patients with cancer.
    Ehmsen S; Asmussen A; Jeppesen SS; Nilsson AC; Østerlev S; Vestergaard H; Justesen US; Johansen IS; Frederiksen H; Ditzel HJ
    Cancer Cell; 2021 Aug; 39(8):1034-1036. PubMed ID: 34348121
    [No Abstract]   [Full Text] [Related]  

  • 28. Oral Vaccination Protects Against Severe Acute Respiratory Syndrome Coronavirus 2 in a Syrian Hamster Challenge Model.
    Johnson S; Martinez CI; Tedjakusuma SN; Peinovich N; Dora EG; Birch SM; Kajon AE; Werts AD; Tucker SN
    J Infect Dis; 2022 Jan; 225(1):34-41. PubMed ID: 34758086
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Single Dose of an MVA Vaccine Expressing a Prefusion-Stabilized SARS-CoV-2 Spike Protein Neutralizes Variants of Concern and Protects Mice From a Lethal SARS-CoV-2 Infection.
    Pérez P; Lázaro-Frías A; Zamora C; Sánchez-Cordón PJ; Astorgano D; Luczkowiak J; Delgado R; Casasnovas JM; Esteban M; García-Arriaza J
    Front Immunol; 2021; 12():824728. PubMed ID: 35154086
    [TBL] [Abstract][Full Text] [Related]  

  • 30. SARS-CoV-2 vaccine candidates in rapid development.
    Li L; Guo P; Zhang X; Yu Z; Zhang W; Sun H
    Hum Vaccin Immunother; 2021 Mar; 17(3):644-653. PubMed ID: 33121319
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vaccination of Pregnant Women Against COVID-19.
    Abu-Raya B
    Neoreviews; 2021 Sep; 22(9):e570-e573. PubMed ID: 34470758
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intranasal vaccination with a lentiviral vector protects against SARS-CoV-2 in preclinical animal models.
    Ku MW; Bourgine M; Authié P; Lopez J; Nemirov K; Moncoq F; Noirat A; Vesin B; Nevo F; Blanc C; Souque P; Tabbal H; Simon E; Hardy D; Le Dudal M; Guinet F; Fiette L; Mouquet H; Anna F; Martin A; Escriou N; Majlessi L; Charneau P
    Cell Host Microbe; 2021 Feb; 29(2):236-249.e6. PubMed ID: 33357418
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein finds additional vaccine-induced epitopes beyond those for mild infection.
    Garrett ME; Galloway JG; Wolf C; Logue JK; Franko N; Chu HY; Matsen FA; Overbaugh JM
    Elife; 2022 Jan; 11():. PubMed ID: 35072628
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intranasal inoculation of an MVA-based vaccine induces IgA and protects the respiratory tract of hACE2 mice from SARS-CoV-2 infection.
    Americo JL; Cotter CA; Earl PL; Liu R; Moss B
    Proc Natl Acad Sci U S A; 2022 Jun; 119(24):e2202069119. PubMed ID: 35679343
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intranasal vaccines for SARS-CoV-2: From challenges to potential in COVID-19 management.
    Chavda VP; Vora LK; Pandya AK; Patravale VB
    Drug Discov Today; 2021 Nov; 26(11):2619-2636. PubMed ID: 34332100
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A class II MHC-targeted vaccine elicits immunity against SARS-CoV-2 and its variants.
    Pishesha N; Harmand TJ; Rothlauf PW; Praest P; Alexander RK; van den Doel R; Liebeskind MJ; Vakaki MA; McCaul N; Wijne C; Verhaar E; Pinney W; Heston H; Bloyet LM; Pontelli MC; Ilagan MXG; Jan Lebbink R; Buchser WJ; Wiertz EJHJ; Whelan SPJ; Ploegh HL
    Proc Natl Acad Sci U S A; 2021 Nov; 118(44):. PubMed ID: 34654739
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gastrointestinal mucosal immunity and COVID-19.
    Velikova T; Snegarova V; Kukov A; Batselova H; Mihova A; Nakov R
    World J Gastroenterol; 2021 Aug; 27(30):5047-5059. PubMed ID: 34497434
    [TBL] [Abstract][Full Text] [Related]  

  • 38. COVID-19 vaccines: The status and perspectives in delivery points of view.
    Chung JY; Thone MN; Kwon YJ
    Adv Drug Deliv Rev; 2021 Mar; 170():1-25. PubMed ID: 33359141
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice.
    Tian JH; Patel N; Haupt R; Zhou H; Weston S; Hammond H; Logue J; Portnoff AD; Norton J; Guebre-Xabier M; Zhou B; Jacobson K; Maciejewski S; Khatoon R; Wisniewska M; Moffitt W; Kluepfel-Stahl S; Ekechukwu B; Papin J; Boddapati S; Jason Wong C; Piedra PA; Frieman MB; Massare MJ; Fries L; Bengtsson KL; Stertman L; Ellingsworth L; Glenn G; Smith G
    Nat Commun; 2021 Jan; 12(1):372. PubMed ID: 33446655
    [TBL] [Abstract][Full Text] [Related]  

  • 40. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
    Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 65.